ArticleAntimicrobial agents and chemotherapy2022
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.
- Dutch guideline for the prevention and control of multidrug-resistant organisms in the hospital setting, 2024 update.Antimicrobial resistance and infection control · 2025Guideline
- Pharmacological advances inJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Beyond antifungal susceptibility: molecular mechanisms, detection, and clinical implications of fungal heteroresistance.Molecular biology reports · 2026Review
- First Case of Bloodstream Infection byAnnals of laboratory medicine · 2026Article
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Clinical implications in patients with isolation of Candidozyma auris in a single tertiary hospital.BMC infectious diseases · 2026Article
- Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026Article
- Recent Outbreaks, Resistance Trends, and Control Measures inJournal of fungi (Basel, Switzerland) · 2026Review
- Evaluation of Sensititre YeastOne for antifungal susceptibility testing ofJournal of clinical microbiology · 2026Article
- Fung-AI: An AI/ML-driven pipeline for antifungal peptide discovery.PLoS computational biology · 2026Article
- Interpretable Quantitative Structure-Activity Relationship (QSAR) for identification of potent antifungal activity agents towards Candida albicans ATCC 2091.Molecular diversity · 2026Article
- Defining thebioRxiv : the preprint server for biology · 2026Article
- Susceptibility of Candida auris isolates to antifungal agents: perspectives from whole-genome sequencing and phenotypic testing.BMC microbiology · 2026Article
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- Potential Antifungal Activity of Retinoids Against Non-Microorganisms · 2026Article
- Review
- Flavonoids as a Potential Antifungal Alternative AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals.Journal of fungi (Basel, Switzerland) · 2026Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
Abstract
Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases in the United States are from the New York and New Jersey Metropolitan area. We performed genome, and drug-resistance analysis of C. auris isolates from a patient who underwent multi-visceral transplantation. Whole-genome comparisons of 19 isolates, collected over 72 days, revealed closed similarity (Average Nucleotide Identity > 0.9996; Aligned Percentage > 0.9764) and a distinct subcluster of NY C. auris South Asia Clade I. All isolates had azole-linked resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.